KEYMED BIOSCIENCES -0001 - Asset Resilience Ratio
KEYMED BIOSCIENCES -0001 (64Z) has an Asset Resilience Ratio of 33.68% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See KEYMED BIOSCIENCES -0001 short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how KEYMED BIOSCIENCES -0001's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see KEYMED BIOSCIENCES -0001 (64Z) total assets.
Liquid Assets Composition Over Time
This chart breaks down KEYMED BIOSCIENCES -0001's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 64Z total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.42 Billion | 33.68% |
| Total Liquid Assets | €1.42 Billion | 33.68% |
Asset Resilience Insights
- Very High Liquidity: KEYMED BIOSCIENCES -0001 maintains exceptional liquid asset reserves at 33.68% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
KEYMED BIOSCIENCES -0001 Industry Peers by Asset Resilience Ratio
Compare KEYMED BIOSCIENCES -0001's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for KEYMED BIOSCIENCES -0001 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for KEYMED BIOSCIENCES -0001.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 33.68% | €1.42 Billion ≈ $1.66 Billion |
€4.22 Billion ≈ $4.93 Billion |
-12.44pp |
| 2024-12-31 | 46.12% | €1.74 Billion ≈ $2.03 Billion |
€3.77 Billion ≈ $4.40 Billion |
-1.99pp |
| 2023-12-31 | 48.11% | €1.87 Billion ≈ $2.18 Billion |
€3.88 Billion ≈ $4.54 Billion |
-17.28pp |
| 2022-12-31 | 65.39% | €2.57 Billion ≈ $3.01 Billion |
€3.93 Billion ≈ $4.60 Billion |
+14.45pp |
| 2021-12-31 | 50.93% | €2.00 Billion ≈ $2.34 Billion |
€3.93 Billion ≈ $4.60 Billion |
-- |
About KEYMED BIOSCIENCES -0001
Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom. The company develops Kangyueda for the treatment of moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis;… Read more